Grammatopoulos George, Kendrick Benjamin, McNally Martin, Athanasou Nicholas A, Atkins Bridget, McLardy-Smith Peter, Taylor Adrian, Gundle Roger
Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford, UK.
J Arthroplasty. 2017 Jul;32(7):2248-2255. doi: 10.1016/j.arth.2017.02.066. Epub 2017 Mar 6.
Debridement-antibiotics-and-implant-retention (DAIR) may be considered a suitable surgical option in periprosthetic joint infections (PJIs) with soundly fixed prostheses, despite chronicity. This study aims to define the long-term outcome following DAIR in hip PJI.
We reviewed all hip DAIRs performed between 1997 and 2013 (n = 122) to define long-term outcome and identify factors influencing it. Data recorded included patient demographics, medical history, type of DAIR performed (+/- exchange of modular components), and organisms identified. Outcome measures included complications and/or mortality rate, implant survivorship, and functional outcome (Oxford Hip Score).
Most DAIRs (67%) were of primary arthroplasties and 60% were performed within 6 weeks from the index arthroplasty. Infection eradication was achieved in 68% of the first DAIR procedure. In 32 cases, more than one DAIR was required. Infection eradication was achieved in 85% of the cases (104/122) with the (single or multiple) DAIR approach. The most common complication was PJI-persistence (15%), followed by dislocation (14%). Very good functional outcomes were obtained, especially in primary arthroplasties. All streptococcus infections were resolved with DAIR and had better outcome. Twenty-one hips have been revised (17%) to-date, 16 were for persistence of PJI. The 10-y implant survivorship was 77%. Early PJI and exchanging modular components at DAIR were independent factors for a 4-fold increased infection eradication and improved long-term implant survival.
DAIR is, therefore, a valuable option in the treatment of hip PJI, especially in the early postoperative period (≤6 weeks), with good outcomes. However, DAIR is associated with increased morbidity; further surgery may be necessary and instability may occur. Where possible, exchange of modular implants should be undertaken.
对于假体周围关节感染(PJI)且假体固定良好的患者,尽管感染已呈慢性,清创-抗生素-保留假体(DAIR)术仍可被视为一种合适的手术选择。本研究旨在明确髋关节PJI行DAIR术后的长期疗效。
我们回顾了1997年至2013年间进行的所有髋关节DAIR手术(n = 122例),以确定长期疗效并找出影响疗效的因素。记录的数据包括患者人口统计学资料、病史、所行DAIR手术类型(是否更换模块化组件)以及鉴定出的微生物。疗效指标包括并发症和/或死亡率、假体生存率以及功能结局(牛津髋关节评分)。
大多数DAIR手术(67%)为初次关节置换术,60%在初次关节置换术后6周内进行。首次DAIR手术中68%实现了感染清除。在32例患者中,需要进行不止一次DAIR手术。采用(单次或多次)DAIR手术方法,85%的病例(104/122)实现了感染清除。最常见的并发症是PJI持续存在(15%),其次是脱位(14%)。获得了非常好的功能结局,尤其是在初次关节置换术中。所有链球菌感染均通过DAIR得到解决,且结局更好。迄今为止,已有21例髋关节进行了翻修(17%),其中16例是因为PJI持续存在。10年假体生存率为77%。早期PJI以及在DAIR手术时更换模块化组件是感染清除率提高4倍和改善长期假体生存率的独立因素。
因此,DAIR是治疗髋关节PJI的一种有价值的选择,尤其是在术后早期(≤6周),疗效良好。然而,DAIR与发病率增加相关;可能需要进一步手术,且可能会出现不稳定。如有可能,应进行模块化假体的更换。